Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP trimmed its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 22.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 41,029 shares of the biopharmaceutical company's stock after selling 12,200 shares during the period. GSA Capital Partners LLP owned approximately 0.07% of Agios Pharmaceuticals worth $1,202,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of AGIO. GAMMA Investing LLC raised its holdings in shares of Agios Pharmaceuticals by 9,296.6% during the 1st quarter. GAMMA Investing LLC now owns 8,175 shares of the biopharmaceutical company's stock worth $240,000 after acquiring an additional 8,088 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in Agios Pharmaceuticals by 3.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company's stock worth $815,000 after acquiring an additional 795 shares during the period. Vanguard Group Inc. increased its position in Agios Pharmaceuticals by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock valued at $185,045,000 after purchasing an additional 85,339 shares during the period. Northern Trust Corp lifted its position in shares of Agios Pharmaceuticals by 0.9% in the 4th quarter. Northern Trust Corp now owns 595,480 shares of the biopharmaceutical company's stock worth $19,567,000 after purchasing an additional 5,372 shares during the period. Finally, Federated Hermes Inc. boosted its position in Agios Pharmaceuticals by 4.4% during the fourth quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock valued at $450,000 after purchasing an additional 582 shares in the last quarter.

Agios Pharmaceuticals Stock Down 6.0%

Shares of Agios Pharmaceuticals stock traded down $2.22 on Friday, reaching $35.00. The company's stock had a trading volume of 2,351,119 shares, compared to its average volume of 723,031. The company has a market capitalization of $2.03 billion, a P/E ratio of 3.18 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a 52-week low of $23.42 and a 52-week high of $62.58. The stock has a 50-day moving average price of $35.69 and a 200-day moving average price of $32.57.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). The business had revenue of $12.50 million during the quarter, compared to analysts' expectations of $9.46 million. Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.39%. Sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Tsveta Milanova sold 2,770 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $92,905.80. Following the completion of the sale, the insider directly owned 26,122 shares in the company, valued at $876,131.88. The trade was a 9.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Cecilia Jones sold 1,780 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $59,701.20. Following the sale, the chief financial officer owned 30,049 shares of the company's stock, valued at $1,007,843.46. The trade was a 5.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 46,363 shares of company stock valued at $1,619,654. 4.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Scotiabank reduced their price target on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a research report on Monday, July 28th. Wall Street Zen cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Finally, Bank of America decreased their target price on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Agios Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $56.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.